| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Ginsenoside Ra2 targets Angiotensin-converting enzyme (ACE). It inhibits ACE with an IC50 of 385.59 µM. By inhibiting ACE, it may have potential effects on blood pressure regulation and the renin-angiotensin system.
|
|---|---|
| ln Vitro |
In vitro, Ginsenoside Ra2 has inhibitory activity against Angiotensin-converting enzyme (ACE) with an IC50 of 385.59 µM. Quantitative IC50 values for its effects on other targets are not detailed in the publicly available sources.
|
| ln Vivo |
In vivo activity data for Ginsenoside Ra2 is limited in publicly available literature. As an ACE inhibitor, it may have potential for blood pressure regulation. However, specific in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been detailed in the available sources. Further research is needed to fully characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
For cell-free assays, the ACE inhibitory activity of Ginsenoside Ra2 can be measured using a standard ACE activity assay. The compound is incubated with purified ACE enzyme and a fluorogenic or chromogenic substrate (e.g., Abz-Gly-p-nitro-Phe-Pro-OH). The rate of substrate cleavage is monitored fluorometrically or spectrophotometrically. The IC50 value is calculated from a dose-response curve.
|
| Cell Assay |
For in vitro cellular assays, the ACE inhibitory activity of Ginsenoside Ra2 can be assessed in cells expressing ACE. Cells are treated with various concentrations of the compound, and ACE activity is measured using a substrate. The IC50 for ACE inhibition is calculated from dose-response curves.
|
| Animal Protocol |
For in vivo studies, Ginsenoside Ra2 could be administered orally in animal models of hypertension. Blood pressure is measured at various time points. Its effect on ACE activity in plasma or tissues can also be assessed.
|
| ADME/Pharmacokinetics |
Ginsenoside Ra2 (CAS 83459-42-1) has a molecular formula of C58H98O26 and a molecular weight of 1211.38 g/mol. Appearance: typically a powder. Solubility: DMSO and other organic solvents. Storage: typical for ginsenosides (desiccated, protected from light, -20°C). Purity: typically >95% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural ginsenoside, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development.
|
| References | |
| Additional Infomation |
Ginsenoside Ra2 is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying ACE inhibition and the renin-angiotensin system. Its mechanism of action involves ACE inhibition. It is a natural product from Panax ginseng. No clinical trials have been reported.
|
| Molecular Formula |
C58H98O26
|
|---|---|
| Molecular Weight |
1211.38
|
| Exact Mass |
1210.634
|
| CAS # |
83459-42-1
|
| PubChem CID |
100941543
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.631
|
| Source |
Originated from plants: Araliaceae Panax ginseng C. A. Meyer
|
| LogP |
4.51
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
26
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
84
|
| Complexity |
2210
|
| Defined Atom Stereocenter Count |
33
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O)O)O)C
|
| InChi Key |
UEBIBJSWHIZNCA-BGPUAMRSSA-N
|
| InChi Code |
InChI=1S/C58H98O26/c1-24(2)10-9-14-58(8,84-51-46(74)42(70)39(67)31(80-51)23-76-52-47(40(68)30(21-61)78-52)82-49-44(72)36(64)27(63)22-75-49)25-11-16-57(7)35(25)26(62)18-33-55(5)15-13-34(54(3,4)32(55)12-17-56(33,57)6)81-53-48(43(71)38(66)29(20-60)79-53)83-50-45(73)41(69)37(65)28(19-59)77-50/h10,25-53,59-74H,9,11-23H2,1-8H3/t25-,26+,27+,28+,29+,30-,31+,32-,33+,34-,35-,36-,37+,38+,39+,40-,41-,42-,43-,44+,45+,46+,47+,48+,49-,50-,51-,52+,53-,55-,56+,57+,58-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S)-4-hydroxy-5-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxolan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~41.3 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (1.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (1.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (1.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8255 mL | 4.1275 mL | 8.2550 mL | |
| 5 mM | 0.1651 mL | 0.8255 mL | 1.6510 mL | |
| 10 mM | 0.0826 mL | 0.4128 mL | 0.8255 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
